This is the second in a series of articles designed to provide SXSW and LSI USA ’26 attendees and other MedTech professionals with practical considerations for efficiently executing mission-critical life science deals.
Collaborations often start with a simple premise: build something together, share the risk, and create value.
The complexity shows up later when investors or buyers ask who actually owns the platform.
In co-development structures involving devices and software, ownership and control are rarely binary. They are defined by layered licensing arrangements, regulatory allocations, manufacturing dependencies, and IP assignments that were often negotiated quickly to get a deal done.
